{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:56:20Z","timestamp":1761155780949},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jbspin.2014.01.019","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T13:05:08Z","timestamp":1396616708000},"page":"362-365","source":"Crossref","is-referenced-by-count":3,"title":["Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis"],"prefix":"10.1016","volume":"81","author":[{"given":"Delphine","family":"Cochereau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Georgin-Lavialle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Dubourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Melboucy-Belkhir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2014.01.019_bib0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1473-3099(07)70081-6","article-title":"Human T-lymphotropic virus 1: recent knowledge about an ancient infection","volume":"7","author":"Verdonck","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CMR.00063-09","article-title":"Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases","volume":"23","author":"Gon\u00e7alves","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcv.2012.12.016","article-title":"HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa","volume":"57","author":"Desdouits","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2008.07557.x","article-title":"Rediscovering alemtuzumab: current and emerging therapeutic roles","volume":"144","author":"Gribben","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"CAMPATH-1H in rheumatoid arthritis\u00a0\u2013\u00a0an intravenous dose-ranging study","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0035","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0040","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1128\/JVI.78.19.10320-10327.2004","article-title":"Direct evidence for a chronic CD8+ T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia\/lymphoma virus type 1-infected patient with sporadic inclusion body myositis","volume":"78","author":"Ozden","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0045","first-page":"2080","article-title":"Alemtuzumab (Campath-1H) for treatment of refractory polymyositis","volume":"35","author":"Thompson","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10875-011-9533-7","article-title":"Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis","volume":"31","author":"Reiff","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0055","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0060","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2012-05-427773","article-title":"Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia","volume":"121","author":"Chen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0070","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood-2005-01-0335","article-title":"Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-alpha-refractory adult T-cell leukemia","volume":"106","author":"Mone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2014.01.019_bib0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s004010050530","article-title":"The main HTLV-I-harboring cells in the muscles of viral carriers with polymyositis are not macrophages but CD4+ lymphocytes","volume":"92","author":"Higuchi","year":"1996","journal-title":"Acta Neuropathol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X14000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X14000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T04:52:15Z","timestamp":1538715135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X14000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1297319X14000438"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2014.01.019","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}